ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1882

30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

Shobhit Piplani1, Priyanshu Jain2, Vladimir Jelic3, Clement Tagoe4 and Beverly Johnson5, 1Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, 2Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, 3Jacobi Medical Center/North Central Bronx, Bronx, NY, 4Albert Einstein College of Medicine, FRESH MEADOWS, NY, 5Albert Einstein College of Medicine, New York, NY

Meeting: ACR Convergence 2024

Keywords: Epidemiology, Health policy, Outcome measures, population studies, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by conducting a comprehensive examination of 30-day readmissions in RA patients, seeking to uncover independent predictors, determine the principal factors contributing to these readmissions and offer insights for targeted interventions to improve healthcare quality in a nationally representative sample of RA patients.

Methods: In this retrospective investigation, the 2019 data from Nationwide Readmission Database were utilized. The primary focus was on determining the rate of readmission for all causes within 30 days post-discharge. Secondary objectives included assessing hospital-level metrics. The identification of independent risk factors for readmission was carried out through Cox regression analysis.

Results: The study examined 7,806 index admissions of RA patients, identifying 90 readmissions. The majority were female (69.15% index, 76.61% readmissions). Medicare covered 58.76% of index cases, decreasing to 40.81% in readmissions. Notably, 35.48% of index and 24.87% of readmitted patients were smokers. Large hospitals (56.22% index, 65.41% readmissions) in metropolitan areas (60.4% index, 63.09% readmissions) were predominant. The most common co-morbidities included hypertension (60.01% index, 55.61% readmissions), osteoarthritis (25.20% index, 15.97% readmissions), and chronic prednisone use (13.91% index, 33.72% readmissions). Most common diagnosis in RA patients’ readmissions included highlighted unspecified RA (M06.9) and Adult-Onset Still’s Disease (M06.1). Age demonstrated a significant inverse association (Adjusted Odds Ratio: 0.96, p< 0.001), while females exhibited a non-significant increase (1.52, p=0.215). Medicaid-insured patients had higher odds (2.77, p< 0.004), but no significant associations were observed for other insurance types. Various co-morbidities, such as Congestive Heart Failure (CHF), showed potential significance (0.036, p=0.097).  Notably, alcohol consumption (4.5, p< 0.0001) and liver conditions (4.09, p< 0.05) emerged as strong positive predictors.

Conclusion: In this nationally representative study, the most substantial risk factors for 30-day readmission in RA patients were female gender, younger age, public insurance, and higher comorbidity scores. Understanding these demographics and co-morbidities is crucial for developing targeted interventions to reduce RA re-admissions. The study recommends early diagnosis, regular monitoring, multidisciplinary care, patient education, and clinical guidelines to reduce readmissions and improve RA patient outcomes.


Disclosures: S. Piplani: None; P. Jain: None; V. Jelic: None; C. Tagoe: None; B. Johnson: Bristol-Myers Squibb(BMS), 5, Genentech, 5, GlaxoSmithKlein(GSK), 5, Janssen, 1, 2, 5, 11, UCB, 2.

To cite this abstract in AMA style:

Piplani S, Jain P, Jelic V, Tagoe C, Johnson B. 30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/30-day-readmission-among-patients-with-rheumatoid-arthritis-and-their-independent-predictors-insights-from-national-readmission-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/30-day-readmission-among-patients-with-rheumatoid-arthritis-and-their-independent-predictors-insights-from-national-readmission-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology